Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future (Q73453363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

editorial

0 references

title

Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

A M de Mattos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

A J Olyaei

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

W M Bennett

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Kidney Diseases

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

333-346

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Cyclosporine: mechanisms of action and toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

The mechanism of action of cyclosporin A and FK506

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Effects of rapamycin in experimental organ allografting

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

The design and development of an immunosuppressive drug, mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Cyclosporin metabolism in transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

The nephrotoxicity of FK506 as compared with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

1 reference

7 January 2021

Toxicity of rapamycin--a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Side effects of rapamycin in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Cyclosporin in therapeutic doses increases renal allograft vascular resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Functional and structural characteristics of experimental FK 506 nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

An analysis of cyclosporine efficacy and toxicity after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

The long-term course of cyclosporine-associated chronic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Cyclosporine nephrotoxicity in lung transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Risks and costs of end-stage renal disease after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Hypertension after cardiac transplantation: pathophysiology and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Sympathetic neural mechanisms of cyclosporine-induced hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

The effects of cyclosporine in Lewis rats with native and transplanted kidneys

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

The plasma creatinine concentration is not an accurate reflection of the glomerular filtration rate in stable renal transplant patients receiving cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Cyclosporin A and its metabolites, distribution in blood and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Important interactions of drugs with immunosuppressive agents used in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Cyclosporine A enhances platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Risk factors for chronic rejection in renal allograft recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Clinically significant drug interactions with new immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

A novel approach to the treatment of chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

The association of cyclosporine with the 1-year costs of cadaver-donor kidney transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

Treatment of renal transplant rejection episodes in patients receiving prednisone and azathioprine. A cost-effective approach

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970348-9

7 January 2021

10.1016/S0272-6386(00)70348-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10676738%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference